Multianalysis with optical coherence tomography and vasomotion in everolimus-eluting stents and everolimus-eluting biovascular scaffolds: the MOVES trial.

Open Heart · 2018 · PMC5761294 · PMID 29344373

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

24 25 Three recently published meta-analyses showed a clear trend towards increased rates of myocardial infarction and stent thrombosis with BVS compared with PP-EES at 1-year follow-up. 26–28 ABOSRB II was designed to show the BVS superiority over PP-EES at 3 years for vasomotion of the stented segment after nitroglycerin administration (mean lumen diameter pre

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.